Compare DexCom, Inc. (DXCM) vs Qurate Retail Inc Series A (QVCAQ) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

QVCAQ trades at $0.088, up 7.32% today but remains deeply distressed with negative shareholder equity of -$971 million. The stock shows a bearish technical signal with 13 sell indicators versus 3 buys. Fundamentally, the company reported a $2.44 billion net loss in 2025 despite $9.23 billion revenue, with negative profit margins and declining revenue trends. Recent news highlights QVC celebrating 40 years of live shopping innovation through TikTok Shop collaborations.

The outlook remains highly risky due to persistent losses, negative equity, and deteriorating balance sheet. While the low P/E of 7.42 and P/B of 0.33 suggest deep value, the negative ROE of -56.13% and mounting debt-to-asset ratio of 77.57% indicate severe financial stress. Investment opportunity exists only for speculative turnaround bets, with bankruptcy risk being substantial given the negative cash flow trends and declining asset base.